Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Information processing speed in multiple sclerosis: Relevance of default mode network dynamics.

van Geest Q, Douw L, van 't Klooster S, Leurs CE, Genova HM, Wylie GR, Steenwijk MD, Killestein J, Geurts JJG, Hulst HE.

Neuroimage Clin. 2018 May 15;19:507-515. doi: 10.1016/j.nicl.2018.05.015. eCollection 2018.

2.

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.

Hagens MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Ciccarelli O, Gasperini C, Lukas C, Wattjes MP, Barkhof F; MAGNIMS Study Group.

Neurology. 2018 Jul 17;91(3):e249-e257. doi: 10.1212/WNL.0000000000005825. Epub 2018 Jun 20.

PMID:
29925550
3.

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.

JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.

PMID:
29532061
4.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

5.

Deep gray matter volume loss drives disability worsening in multiple sclerosis.

Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group.

Ann Neurol. 2018 Feb;83(2):210-222. doi: 10.1002/ana.25145. Epub 2018 Feb 6.

6.

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

Hagens MH, Burggraaff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Wuerfel J, Ciccarelli O, Gasperini C, Lukas C, Rovira A, Barkhof F, Wattjes MP; MAGNIMS Study Group.

Mult Scler. 2018 Jan 1:1352458517751647. doi: 10.1177/1352458517751647. [Epub ahead of print]

PMID:
29327668
7.

Gray matter networks and cognitive impairment in multiple sclerosis.

Rimkus CM, Schoonheim MM, Steenwijk MD, Vrenken H, Eijlers AJ, Killestein J, Wattjes MP, Leite CC, Barkhof F, Tijms BM.

Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650. [Epub ahead of print]

PMID:
29320933
8.

Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?

Sestito C, Brevé JJP, van Eggermond MCJA, Killestein J, Teunissen CE, van Rossum J, Wilhelmus MMM, Drukarch B, van den Elsen PJ, van Dam AM.

J Neuroinflammation. 2017 Dec 21;14(1):257. doi: 10.1186/s12974-017-1035-y.

9.

Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS.

Bruinsma IB, van Dijk M, Bridel C, van de Lisdonk T, Haverkort SQ, Runia TF, Steinman L, Hintzen RQ, Killestein J, Verbeek MM, Teunissen CE, de Jong BA.

J Neuroinflammation. 2017 Dec 4;14(1):235. doi: 10.1186/s12974-017-1006-3.

10.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
11.

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.

Dekker I, Sombekke MH, Witte BI, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2018 Apr;24(4):481-490. doi: 10.1177/1352458517736147. Epub 2017 Nov 6.

12.

Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

van Kempen ZL, Rispens T, Killestein J.

Mult Scler. 2018 May;24(6):822-823. doi: 10.1177/1352458517734073. Epub 2017 Oct 9. No abstract available.

13.

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381. [Epub ahead of print]

PMID:
28823223
14.

Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.

Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In 't Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, de Jager SC, Urbanus RT, Hoefer IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T.

Cancer Cell. 2017 Aug 14;32(2):238-252.e9. doi: 10.1016/j.ccell.2017.07.004.

15.

Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.

Killestein J, Leurs CE, Hoogervorst ELJ, van Eijk J, Mostert JP, van den Eertwegh AJM, Uitdehaag BMJ.

Neurology. 2017 Aug 29;89(9):970-972. doi: 10.1212/WNL.0000000000004293. Epub 2017 Aug 2. No abstract available.

PMID:
28768850
16.

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

van Kempen ZLE, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, Killestein J.

Eur J Neurol. 2017 Sep;24(9):1196-1199. doi: 10.1111/ene.13355. Epub 2017 Jul 14.

PMID:
28707781
17.

Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro.

Bridel C, Koel-Simmelink MJA, Peferoen L, Derada Troletti C, Durieux S, Gorter R, Nutma E, Gami P, Iacobaeus E, Brundin L, Kuhle J, Vrenken H, Killestein J, Piersma SR, Pham TV, De Vries HE, Amor S, Jimenez CR, Teunissen CE.

Neuropathol Appl Neurobiol. 2018 Jun;44(4):404-416. doi: 10.1111/nan.12412. Epub 2017 Jun 28.

PMID:
28543098
18.

Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.

Balk LJ, Coric D, Nij Bijvank JA, Killestein J, Uitdehaag BM, Petzold A.

Mult Scler. 2018 May;24(6):767-776. doi: 10.1177/1352458517708463. Epub 2017 May 17.

19.

Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.

Warnke C, Wijburg MT, Hartung HP, Killestein J, Adams O, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1092-1094. doi: 10.1136/jnnp-2016-315298. Epub 2017 May 10. No abstract available.

PMID:
28490505
20.

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.

van Kempen ZL, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T, Killestein J.

Mult Scler. 2018 May;24(6):805-810. doi: 10.1177/1352458517708464. Epub 2017 May 9.

21.

Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.

Hagens MH, Killestein J, Yaqub MM, van Dongen GA, Lammertsma AA, Barkhof F, van Berckel BN.

Mult Scler. 2018 Apr;24(4):543-545. doi: 10.1177/1352458517704507. Epub 2017 Apr 26.

22.

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.

Leurs CE, Podlesniy P, Trullas R, Balk L, Steenwijk MD, Malekzadeh A, Piehl F, Uitdehaag BM, Killestein J, van Horssen J, Teunissen CE.

Mult Scler. 2018 Apr;24(4):472-480. doi: 10.1177/1352458517699874. Epub 2017 Mar 15.

23.

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.

Coric D, Balk LJ, Verrijp M, Eijlers A, Schoonheim MM, Killestein J, Uitdehaag BM, Petzold A.

Mult Scler. 2018 Feb;24(2):158-166. doi: 10.1177/1352458517694090. Epub 2017 Feb 1.

24.

Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-Tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis.

van Amerongen G, Kanhai K, Baakman AC, Heuberger J, Klaassen E, Beumer TL, Strijers RLM, Killestein J, van Gerven J, Cohen A, Groeneveld GJ.

Clin Ther. 2017 Feb 9. pii: S0149-2918(17)30054-1. doi: 10.1016/j.clinthera.2017.01.016. [Epub ahead of print]

PMID:
28189366
25.

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Jun;23(7):995-999. doi: 10.1177/1352458516684023. Epub 2016 Dec 13.

PMID:
28112019
26.

An observational study of alemtuzumab following fingolimod for multiple sclerosis.

Willis M, Pearson O, Illes Z, Sejbaek T, Nielsen C, Duddy M, Petheram K, van Munster C, Killestein J, Malmeström C, Tallantyre E, Robertson N.

Neurol Neuroimmunol Neuroinflamm. 2017 Jan 10;4(2):e320. doi: 10.1212/NXI.0000000000000320. eCollection 2017 Mar.

27.

Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis.

Malekzadeh A, Twaalfhoven H, Wijnstok NJ, Killestein J, Blankenstein MA, Teunissen CE.

Cytokine. 2017 Mar;91:145-152. doi: 10.1016/j.cyto.2016.12.021. Epub 2017 Jan 9.

PMID:
28082233
28.

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site.

van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T.

J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. doi: 10.1016/j.jaci.2016.09.014. Epub 2016 Oct 4. No abstract available.

PMID:
27717666
29.

MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.

Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Uitdehaag BM, Barkhof F, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1138-45. doi: 10.1136/jnnp-2016-313772. Epub 2016 Aug 16.

PMID:
27530808
30.

Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Maas RP, Muller-Hansma AH, Esselink RA, Murk JL, Warnke C, Killestein J, Wattjes MP.

J Neurol. 2016 Oct;263(10):2004-21. doi: 10.1007/s00415-016-8217-x. Epub 2016 Jul 11.

31.

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.

Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Gelfand JM, Tewarie P, Killestein J, Uitdehaag BM, Petzold A, Green AJ.

J Neurol. 2016 Jul;263(7):1323-31. doi: 10.1007/s00415-016-8127-y. Epub 2016 May 3.

32.

CSF examination still has value in the diagnosis of MS - NO.

Killestein J, Uitdehaag BM.

Mult Scler. 2016 Jul;22(8):995-7. doi: 10.1177/1352458516641777. Epub 2016 Apr 8. No abstract available.

PMID:
27059062
33.

High cumulative JC virus seroconversion rate during long-term use of natalizumab.

Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.

Eur J Neurol. 2016 Jun;23(6):1079-85. doi: 10.1111/ene.12988. Epub 2016 Mar 27.

PMID:
27018481
34.

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.

Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr.

35.

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.

de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, van der Pouw Kraan TC, Leurs C, Hegen H, Deisenhammer F, Killestein J, Lundberg IE, Vencovsky J, Nurmohamed MT, van Schaardenburg D, Bultink IE, Voskuyl AE, Pegtel DM, van der Laken CJ, Bijlsma JW, Verweij CL.

Arthritis Res Ther. 2016 Feb 17;18:49. doi: 10.1186/s13075-016-0946-9.

36.

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML.

Wijburg MT, Siepman D, van Eijk JJ, Killestein J, Wattjes MP.

J Neurol. 2016 Apr;263(4):649-56. doi: 10.1007/s00415-015-8001-3. Epub 2016 Jan 25.

37.

Cannabinoids in the Treatment of Epilepsy.

Killestein J.

N Engl J Med. 2016 Jan 7;374(1):94. doi: 10.1056/NEJMc1512758. No abstract available.

PMID:
26672646
38.

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Richert ND, Uitdehaag BM, Barkhof F, Killestein J.

Mult Scler. 2016 Aug;22(9):1174-83. doi: 10.1177/1352458515615225. Epub 2015 Nov 12.

PMID:
26564995
39.

Low JC virus antibody index during natalizumab treatment less safe than assumed?

Killestein J, Wattjes MP.

Mult Scler. 2015 Dec;21(14):1753-4. doi: 10.1177/1352458515611499. Epub 2015 Oct 8. No abstract available.

PMID:
26449744
40.

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.

Bustamante MF, Morcillo-Suárez C, Malhotra S, Rio J, Leyva L, Fernández O, Zettl UK, Killestein J, Brassat D, García-Merino JA, Sánchez AJ, Urcelay E, Alvarez-Lafuente R, Villar LM, Alvarez-Cermeño JC, Farré X, Lechner-Scott J, Vandenbroeck K, Rodríguez-Antigüedad A, Drulovic JS, Martinelli Boneschi F, Chan A, Oksenberg J, Navarro A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e154. doi: 10.1212/NXI.0000000000000154. eCollection 2015 Oct.

41.

Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Teunissen CE, Malekzadeh A, Leurs C, Bridel C, Killestein J.

Nat Rev Neurol. 2015 Oct;11(10):585-96. doi: 10.1038/nrneurol.2015.173. Epub 2015 Sep 22. Review.

PMID:
26392381
42.

MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BM, Barkhof F, Killestein J; Dutch-Belgian Natalizumab-associated PML study group.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):879-84. doi: 10.1136/jnnp-2015-311411. Epub 2015 Sep 14.

PMID:
26369555
43.

Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis.

Daams M, Steenwijk MD, Schoonheim MM, Wattjes MP, Balk LJ, Tewarie PK, Killestein J, Uitdehaag BM, Geurts JJ, Barkhof F.

Mult Scler. 2016 Apr;22(5):608-19. doi: 10.1177/1352458515596598. Epub 2015 Jul 24.

PMID:
26209593
44.

Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis.

Daams M, Steenwijk MD, Wattjes MP, Geurts JJ, Uitdehaag BM, Tewarie PK, Balk LJ, Pouwels PJ, Killestein J, Barkhof F.

Neurology. 2015 Jul 21;85(3):248-55. doi: 10.1212/WNL.0000000000001756. Epub 2015 Jun 26.

PMID:
26115736
45.

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate.

Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC, Van Hecke W, Frijlink DW, Wattjes MP; PML in Dutch MS Patients Consortium.

N Engl J Med. 2015 Apr 9;372(15):1474-6. doi: 10.1056/NEJMc1413724. No abstract available.

46.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G.

Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.

PMID:
25680984
47.

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.

Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.

Mult Scler. 2015 Oct;21(12):1600-3. doi: 10.1177/1352458514567728. Epub 2015 Feb 6.

PMID:
25662344
48.

NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.

Malhotra S, Río J, Urcelay E, Nurtdinov R, Bustamante MF, Fernández O, Oliver B, Zettl U, Brassat D, Killestein J, Lechner-Scott J, Drulovic J, Chan A, Martinelli-Boneschi F, García-Merino A, Montalban X, Comabella M.

Brain. 2015 Mar;138(Pt 3):644-52. doi: 10.1093/brain/awu388. Epub 2015 Jan 12.

49.

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.

Killestein J, Vennegoor A, van Golde AE, Bourez RL, Wijlens ML, Wattjes MP.

Case Rep Neurol Med. 2014;2014:307872. doi: 10.1155/2014/307872. Epub 2014 Nov 23.

50.

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature.

Wijburg MT, van Oosten BW, Murk JL, Karimi O, Killestein J, Wattjes MP.

J Neurol. 2015 Jan;262(1):65-73. doi: 10.1007/s00415-014-7530-5. Epub 2014 Oct 9. Review.

PMID:
25297924

Supplemental Content

Loading ...
Support Center